당뇨병성 말초혈관병증 환자에게 Beraprost Sodium이 미치는영향에 대한 적외선 체열검사를 통한 연구
Effects of Beraprost Sodium Evaluated by Digital Infrared Thermal Imaging in Diabetic Patients with Peripheral Arterial Disease
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: This study examined the effects of beraprost sodium on digital infrared thermal images in patients with peripheral arterial disease caused by type 2 diabetes mellitus. Materials and Methods: Twenty-five diabetic patients with peripheral arterial disease were treated with beraprost sodium in a prospective, multicenter, cohort study from February 2013 to December 2014. Beraprost sodium (40 µg) was administered orally 3 times daily (120 µg/day) for 6 months. The visual analogue scale (VAS) and digital infrared thermal imaging (DITI) were performed to compare the blood flow improvement between before and after dosing. Results: Among the 25 patients included in the evaluation, 22 patients completed the study. A significant increase in body temperature was observed in the front and left side, particularly in the plantar side in DITI compared to that before and after administration. An increase in body temperature was observed at the frontal part from 28.1°C±2.3°C to 29.1°C±2.1°C (p=0.021), at the left side from 27.8°C±2.4°C to 28.6°C±1.9°C (p=0.028), at the plantar part at 24.0°C±1.5°C, and at the plantar part at 27.1°C±2.4°C (p<0.01). The VAS decreased significantly from 5.4±1.3 to 2.7±2.0 after 6 months of treatment (p<0.01). Conclusion: Beraprost sodium is a safe and easy-to use oral medication for diabetes peripheral arterial disease. It can be expected to increase the blood flow and decrease the lower extremity pain statistically after being taken for 6 months.
Abstract
Purpose: This study examined the effects of beraprost sodium on digital infrared thermal images in patients with peripheral arterial disease caused by type 2 diabetes mellitus. Materials and Methods: Twenty-five diabetic patients with peripheral arterial disease were treated with beraprost sodium in a prospective, multicenter, cohort study from February 2013 to December 2014. Beraprost sodium (40 µg) was administered orally 3 times daily (120 µg/day) for 6 months. The visual analogue scale (VAS) and digital infrared thermal imaging (DITI) were performed to compare the blood flow improvement between before and after dosing. Results: Among the 25 patients included in the evaluation, 22 patients completed the study. A significant increase in body temperature was observed in the front and left side, particularly in the plantar side in DITI compared to that before and after administration. An increase in body temperature was observed at the frontal part from 28.1°C±2.3°C to 29.1°C±2.1°C (p=0.021), at the left side from 27.8°C±2.4°C to 28.6°C±1.9°C (p=0.028), at the plantar part at 24.0°C±1.5°C, and at the plantar part at 27.1°C±2.4°C (p<0.01). The VAS decreased significantly from 5.4±1.3 to 2.7±2.0 after 6 months of treatment (p<0.01). Conclusion: Beraprost sodium is a safe and easy-to use oral medication for diabetes peripheral arterial disease. It can be expected to increase the blood flow and decrease the lower extremity pain statistically after being taken for 6 months.
참고문헌 (20)
- "Diabetes fact sheet in Korea 2016" (2016)[URL]
- Singh N, "Preventing foot ulcers in patients with diabetes", JAMA, 293, pp.217~228 (2005)
- Lipsky BA, "Developing and validating a risk score for lower-extremity amputation in patients hospitalized for a diabetic foot infection", Diabetes Care, 34, pp.1695~1700 (2011)
- Hang Seob Yoon, "Effects of Beraprost Sodium on Subjective Symptoms in Diabetic Patients with Peripheral Arterial Disease", Clinics in Orthopedic Surgery, 5(2), pp.145~151 (2013), 대한정형외과학회
- Demolis JL, "Pharmacokinetics and platelet antiaggregating effects of beraprost, an oral stable prostacyclin analogue, in healthy volunteers", J Cardiovasc Pharmacol, 22, pp.711~716 (1993)
- Lièvre M, "Oral beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermettente (BERCI)research group", Circulation, 102, pp.426~431 (2000)
- Nony P, "Platelet-aggregation inhibition and hemodynamic effects of beraprost sodium, a new oral prostacyclin derivative : a study in healthy male subjects", Can J Physiol Pharmacol, 74, pp.887~893 (1996)
- Uchikawa T, "Effects of the anti-platelet agent cilostazol on peripheral vascular disease in patients with diabetes mellitus", Arzneimittelforschung, 42, pp.322~324 (1992)
- Beebe HG, "A new pharmacological treatment for intermittent claudication : results of a randomized, multicenter trial", Arch Intern Med, 159, pp.2041~2050 (1999)
- Dawson DL, "A comparison of cilostazol and pentoxifylline for treating intermittent claudication", Am J Med, 109, pp.523~530 (2000)
- Dawson DL, "Cilostazol has beneficial effects in treatment of intermittent claudication : results from a multicenter, randomized, prospective, double-blind trial", Circulation, 98, pp.678~686 (1998)
- Marso SP, "Peripheral arterial disease in patients with diabetes", J Am Coll Cardiol, 47, pp.921~929 (2006)
- Belch JJ, "Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication", Circulation, 95, pp.2298~2302 (1997)
- Müller-Bühl U, "Clinical effects of intravenous iloprost in patients with intermittent claudication", Eur J Clin Pharmocol, 33, pp.127~131 (1987)
- Friedman R, "Continuous infusion of prostacyclin normalizes plasma markers of endothelial cell injury and platelet aggregation in primary pulmonary hypertension", Circulation, 96, pp.2782~2784 (1997)
- Vane JR, "Pharmacodynamic profile of prostacyclin", Am J Cardiol, 75, pp.3A~10A (1995)
- Goya K, "Effects of the prostaglandin I2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus", Metabolism, 52, pp.192~198 (2003)
- Galiè N, "Prostanoids for pulmonary arterial hypertension", Am J Respir Med, 2, pp.123~137 (2003)
- Ueno Y, "Effects of beraprost sodium, a prostacyclin analogue, on diabetic neuropathy in streptozotocin-induced diabetic rats", Jpn J Pharmacol, 70, pp.177~182 (1996)
- Aso Y, "Changes in skin blood flow in type 2 diabetes induced by prostacyclin : association with ankle brachial index and plasma throbomodulin levels", Metabolism, 50, pp.568~572 (2001)